文献速递病毒性肝炎

接受新型抗癌治疗的癌症患者中乙型肝炎病毒和丙型肝炎病毒的再激活

Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies.
PubMed 文献 · Clin Microbiol Infect · 2022-03-10

本叙述性综述检索了2013年7月至2021年12月间MEDLINE收录的英文原始研究、病例报告和系统综述,描述接受新型系统性抗癌治疗的HBV或HCV感染癌症患者中病毒再激活的发生率、特征和结局。接受免疫检查点抑制剂、BTK抑制剂、靶向CD22/CD38/CCR4药物及CAR-T细胞治疗的患者中再激活风险尚未明确,但建议筛查慢性HBV和HCV感染并在治疗期间常规监测,以早期识别可能影响肿瘤治疗结局或致命的再激活。

要点

  • 新型抗癌治疗(免疫检查点抑制剂、BTK抑制剂、CAR-T等)中HBV/HCV再激活风险尚未明确。
  • 建议对接受新型抗癌治疗者筛查慢性HBV和HCV感染。
  • 对合并感染者建议在新型抗癌治疗期间常规监测以及早识别再激活。

核心结论

  • 接受新型系统性抗癌治疗的癌症患者中HBV或HCV再激活风险尚未明确,但建议筛查慢性HBV和HCV感染并在治疗期间常规监测,以早期识别可能影响肿瘤治疗结局或致命的再激活。
  • 应设计针对慢性HBV或HCV感染患者新型抗癌治疗后再激活的风险评估、监测和管理策略。

研究设计与样本

  • 叙述性综述,检索MEDLINE中2013年7月至2021年12月发表的英文原始研究、病例报告和系统综述,纳入接受新型系统性抗癌治疗的HBV或HCV感染癌症患者。

主要发现

  • 接受免疫检查点抑制剂(度伐利尤单抗、阿替利珠单抗、纳武利尤单抗、帕博利珠单抗、伊匹木单抗和替西木单抗)的患者中HBV或HCV再激活风险尚未明确。
  • 接受BTK抑制剂(伊布替尼和阿可替尼)的患者中HBV或HCV再激活风险尚未明确。
  • 接受靶向CD22(奥加伊妥珠单抗)、CD38(达雷妥尤单抗、伊沙妥昔单抗)和CCR4(莫格利珠单抗)药物的患者中HBV或HCV再激活风险尚未明确。
  • 接受CAR-T细胞治疗(阿基仑赛)的患者中HBV或HCV再激活风险尚未明确。

关键数值与推荐

  • 建议对接受新型抗癌治疗的患者筛查慢性HBV和HCV感染。
  • 建议对合并慢性HBV或HCV感染的患者在新型抗癌治疗期间常规监测,以早期识别病毒再激活。

临床怎么用

  • 对接受新型系统性抗癌治疗的癌症患者,建议筛查慢性HBV和HCV感染。
  • 对合并慢性HBV或HCV感染并接受新型抗癌治疗的患者,建议在治疗期间常规监测以早期识别再激活。
  • 作者认为应设计针对慢性HBV或HCV感染患者新型抗癌治疗后再激活的风险评估、监测和管理策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are at high risk of viral reactivation after cancer treatment. However, there is a paucity of data regarding HBV or HCV reactivation in cancer patients who receive newer anticancer drugs such as immune checkpoint inhibitors; Bruton tyrosine kinase (BTK) inhibitors; agents targeting CD22, CD38, and CC chemokine receptor 4 (CCR4); and chimeric antigen receptor (CAR) T-cell therapies. OBJECTIVES: In this narrative review article, we describe the rate, characteristics, and outcomes of HBV and HCV reactivation in patients receiving novel systemic anticancer therapies. SOURCES: We searched MEDLINE for all original research articles, case reports, and systematic reviews published in English between July 2013 and December 2021 on cancer patients with HBV or HCV infection receiving novel systemic anticancer therapy. CONTENT: The risk of HBV or HCV reactivation is not well defined in cancer patients receiving immune checkpoint inhibitors (durvalumab, atezolizumab, nivolumab, pembrolizumab, ipilimumab, and tremelimumab); BTK inhibitors (ibrutinib and acalabrutinib); agents targeting CD22 (inotuzumab ozogamicin), CD38 (daratumumab, isatuximab), and CCR4 (mogamulizumab); and CAR T-cell therapy (axicabtagene-ciloleucel). However, screening for chronic HBV and HCV infections and routine monitoring of patients with such infections during novel anticancer therapy are recommended for early identification of viral reactivation, which can impact outcomes of oncologic treatment or be fatal. IMPLICATIONS: Specific strategies for risk assessment, monitoring, and management should be designed to reduce the risk of reactivation after novel anticancer therapy in patients with chronic HBV or HCV infections.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect. 2022. PMID: 35283317. doi:10.1016/j.cmi.2022.02.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。